Pilot/Pivotal Study of DBS+Rehab After Stroke
- Conditions
- Upper Extremity ParesisStroke
- Interventions
- Other: RehabilitationDevice: Deep Brain Stimulation
- Registration Number
- NCT05701280
- Lead Sponsor
- Enspire DBS Therapy, Inc.
- Brief Summary
The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.
- Detailed Description
The RESTORE Stroke Study combines two phases of study under one protocol (pilot/pivotal). The first phase has a sample size of 40 subjects. The second phase has an estimated sample size of 162 subjects which may be adjusted based on analysis of the first phase.
Each subject will be implanted with the DBS system, undergo DBS program optimization, and be randomized to test treatment (Tt) or active-control treatment (Ct). After randomization, all subjects will participate in a five-month outpatient rehabilitation therapy program. After five months of blinded randomized testing, subjects assigned to active-control treatment (Ct) will cross over to receive test treatment (Tt) and participate in a second five-month therapy program.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 202
- Ischemic stroke, with an initial incident occurring between 12 months to 6 years before implant, resulting in residual upper extremity hemiparesis.
Key
- Previous or subsequent cerebrovascular events resulting in residual upper extremity impairment
- Brain lesions with significant involvement of the brainstem, cerebellum, or thalamus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Rehab Rehabilitation Control-DBS combined with motor rehabilitation DBS+Rehab Deep Brain Stimulation Active-DBS combined with motor rehabilitation
- Primary Outcome Measures
Name Time Method Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE) Week-12 to Week-32 The change in FMA-UE is significantly greater for subjects who receive Test treatment (Tt) than Control treatment (Ct).
- Secondary Outcome Measures
Name Time Method Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE) Week-12 to Week-32 The change in FMA-UE for subjects who receive Test treatment (Tt) is significantly above a clinically important difference (CID)
Trial Locations
- Locations (7)
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
Barrow Neurological Institute (BNI)
🇺🇸Phoenix, Arizona, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Medical University of South Carolina (MUSC)
🇺🇸Charleston, South Carolina, United States